Composition for preventing or treating chronic kidney disease, comprising compound that induces expression of anti-aging gene klotho

1 . A method for preventing or treating chronic kidney disease, the method comprising administering a pharmaceutical composition comprising a compound represented by the following Chemical Formula 1 or a pharmaceutically acceptable salt thereof to a subject in need thereof:

wherein,

L 1 is a single bond or

R 1 and R 2 are each —H, —OH, a C 1-10 straight or branched alkyl, or a C 6-8 arylamide, wherein the aryl of the arylamide is optionally substituted with one or more of a halogen, —NO 2 and a C 1-10 straight or branched alkyl halide;

R 1 and R 2 optionally form a C 6-8 aryl with a carbon atom to which they are linked; and

R 3 , R 4 , R 5 , R 6 and R 7 are each —H, a halogen, —NO 2 or a C 1-10 straight or branched alkyl.

2 . The method of claim 1 , wherein L 1 is a single bond or

R 1 and R 2 are each —H, —OH, a C 1-5 straight or branched alkyl, or a C 6-7 arylamide, wherein the aryl of the arylamide is optionally substituted with one or more of a halogen, —NO 2 and a C 1-5 straight or branched alkyl halide; R 1 and R 2 optionally form a C 6-7 aryl with a carbon atom to which they are linked; and R 3 , R 4 , R 5 , R 6 and R 7 are each —H, a halogen, —NO 2 or a C 1-5 straight or branched alkyl.

3 . The method of claim 1 , wherein L 1 is a single bond or

R 1 and R 2 are each —H, —OH, —CH 3 , or phenylamide, wherein the phenyl of the phenylamide is optionally substituted with one or more of —Cl, —NO 2 and —CH 2 Cl; R 1 and R 2 optionally form a phenyl with a carbon atom to which they are linked; and R 3 , R 4 , R 5 , R 6 and R 7 are each —H, —F, —Cl, —NO 2 or —CH 2 CH 3 .

4 . The method of claim 1 , wherein L 1 is a single bond or

R 1 is —H; —OH, —CH 3 ,

R 2 is —H; R 1 and R 2 optionally form a phenyl with a carbon atom to which they are linked; R 3 is —H or —Cl; R 4 is —H, —F or —Cl; R 5 is —F, —Cl, —NO 2 , or —CH 2 CH 3 ; R 6 is —H; and R 7 is —H.

5 . The method of claim 1 , wherein the compound represented by Chemical Formula 1 is any one selected from the following compound group:

1) N-(benzo[d]oxazol-2-yl)-2-chloro-4-nitrobenzamide;

2) 8-methyl-2-[N-(3,4-dichlorophenyl)]aminobenzoxazole;

3) 2-((3,4-dichlorophenyl)amino)benzo[d]oxazol-5-ol;

4) N-(2-(4-ethylphenylamino)benzo[d]oxazol-5-yl)-2-chloro-5-nitrobenzamide;

5) N-(2-(4-ethylphenylamino)benzo[d]oxazol-5-yl)-3,4-dichlorobenzamide;

6) N-(2-(4-ethylphenylamino)benzo[d]oxazol-5-yl)-3-(chloromethyl)benzamide;

7) 2-[N-(3,4-dichlorophenyl)]aminobenzoxazole;

8) N-(3,4-dichlorophenyl)naphtho[2,3-d]oxazol-2-amine;

9) N-(3,4-difluorophenyl)-5-methylbenzo[d]oxazol-2-amine; and

10) N-(3,4-difluorophenyl)benzo[d]oxazol-2-amine.

6 . The method of claim 1 , wherein the compound represented by the Chemical Formula 1 is a compound represented by the following Chemical Formula 1-1:

wherein,

L 1 is a single bond;

R 1 and R 2 are each —H, or C 1-10 straight or branched chain alkyl;

R 3 , R 4 , R 5 , R 6 and R 7 are each —H or halogen.

7 . The method of claim 1 , wherein the composition increases the expression level of a klotho gene.

8 . The method of claim 1 , wherein the chronic kidney disease is defined as a disease state in which there is kidney damage or decreased kidney function lasting more than three months.

9 . The method of claim 1 , wherein the chronic kidney disease comprises one or more conditions selected from the group consisting of chronic nephritis, chronic pyelonephritis, nephrotic syndrome, chronic pyelonephritis, urinary tract infection, diabetic nephropathy, chronic glomerulonephritis, nephroze syndrome, microglomerular sclerosis, membranous nephropathy, and membranoproliferative glomerulonephritis.